S-Allylcysteine



Compound IDCDAMM00808
Common nameS-Allylcysteine
IUPAC name2-amino-3-prop-2-enylsulfanylpropanoic acid
Molecular formulaC6H11NO2S

Experimental data

Retention time10.06
Adduct[M+Na]+
Actual mz184.04
Theoretical mz184.04
Error1.53
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score7.1372

Identifiers and class information

Inchi keyZFAHNWWNDFHPOH-UHFFFAOYNA-N
SmilesO=C(O)C(N)CSCC=C
SuperclassOrganic acids and derivatives
ClassCarboxylic acids and derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)0
Number of non-conjugated amine groups (#amine)1
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)6
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-1
Molecular weight (mol_MW)161.218
Computed dipole moment(dipole)6.61
Total solvent accessible surface area (SASA)391.362
Hydrophobic component of SASA (FOSA)161.628
Hydrophilic component of SASA (FISA)150.444
Pie component of the SASA (PISA)47.127
Weakly polar component of the SASA (WPSA)32.163
Total solvent accesible volume (volume)604.894
Number of hydrogen bond donors (donorHB)3
Number of hydrogen bond acceptors (accptHB)3.5
Free energy of solvation of dipole (dip^2/V)0.0722302
Index of cohesive interaction in solids (ACxDN^.5/SA)0.01549
Globularity descriptor (glob)0.883838
Predicted polarizability in cubic angstroms (QPpolrz)14.651
Predicted hexadecane/gas partition coefficient (QPlogPC16)5.973
Predicted octanol/gas partition coefficient (QPlogPoct)11.503
Predicted water/gas partition coefficient (QPlogPw)8.534
Predicted octanol/water partition coefficient (QPlogPo/w)-1.425
Predicted aqueous solubility (QPlogS)-0.753
Conformation-independent predicted aqueous solubility (CIQPlogS)-0.13
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-2.555
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)23.428
Predicted brain/blood partition coefficient (QPlogBB)-0.605
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)18.061
Predicted skin permeability, log Kp (QPlogKp)-5.613
PM3 calculated ionization potential (IP(ev))9.337
PM3 calculated electron affinity (EA(eV))0.509
Number of likely metabolic reactions (#metab)4
Prediction of binding to human serum albumin (QPlogKhsa)-0.861
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)43.12
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)74.346
Number of nitrogen and oxygen atoms (#NandO)3
Number of violations of Lipinski’s rule of five (RuleOfFive)0
Number of violations of Jorgensen’s rule of three (RuleOfThree)0

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P35228NOS2Nitric oxide synthase, inducibleT02703SEA
O00222GRM8Metabotropic glutamate receptor 8T77548SEA
Q4U2R8SLC22A6Solute carrier family 22 member 6 (by homology)T70680SEA
P43005SLC1A1Excitatory amino acid transporter 3T31721SEA
P39086GRIK1Glutamate receptor ionotropic kainate 1T73495SEA
Q13002GRIK2Glutamate receptor ionotropic kainate 2T58178SEA
O15303GRM6Metabotropic glutamate receptor 6T55956SEA
Q16478GRIK5Glutamate receptor ionotropic kainate 5T87930SEA
Q13003GRIK3Glutamate receptor ionotropic kainate 3T68876SEA
Q16719KYNUKynureninaseT99912SEA
Q01650SLC7A5L-type amino acid transporter 1 (by homology)T48330SEA
P52732KIF11Kinesin-like protein 1T28484SEA
P14384CPMCarboxypeptidase MT65483SEA
O60603TLR2Toll-like receptor 2T82078SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T02703DI0083Chronic kidney disease[ICD-11: GB61]P35228NOS2
T02703DI0320Osteoarthritis[ICD-11: FA00-FA05]P35228NOS2
T02703DI0375Sepsis[ICD-11: 1G40-1G41]P35228NOS2
T02703DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P35228NOS2
T70680DI0167Gout[ICD-11: FA25]Q4U2R8SLC22A6
T70680DI0206Inborn purine/pyrimidine/nucleotide metabolism error[ICD-11: 5C55]Q4U2R8SLC22A6
T70680DI0310Ocular disease[ICD-11: N.A.]Q4U2R8SLC22A6
T73495DI0134Epilepsy/seizure[ICD-11: 8A61-8A6Z]P39086GRIK1
T73495DI0396Substance abuse[ICD-11: 6C40]P39086GRIK1
T99912DI0046Bacterial infection[ICD-11: 1A00-1C4Z]Q16719KYNU
T99912DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q16719KYNU
T28484DI0012Acute myeloid leukaemia[ICD-11: 2A60]P52732KIF11
T28484DI0172Head and neck cancer[ICD-11: 2D42]P52732KIF11
T28484DI0241Lymphoma[ICD-11: 2A80-2A86]P52732KIF11
T28484DI0245Malignant haematopoietic neoplasm[ICD-11: 2B33]P52732KIF11
T28484DI0274Multiple myeloma[ICD-11: 2A83]P52732KIF11
T28484DI0321Ovarian cancer[ICD-11: 2C73]P52732KIF11
T28484DI0361Renal cell carcinoma[ICD-11: 2C90]P52732KIF11
T28484DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P52732KIF11
T82078DI0346Prostate cancer[ICD-11: 2C82]O60603TLR2

Copyright © 2025